Streetbeat News

Earnings

DERM

Journey Medical (NASDAQ:DERM) reported Q4 2023 earnings of $0.03 per share, surpassing the $(0.08) estimate, with sales of $15.257M beating the $15.061M estimate, despite a 4.44% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 9:03 pm

FDX

UPS

United Parcel Service, Inc. (UPS) shares rose after hours in response to FedEx Corp's (FDX) positive third-quarter earnings report. FedEx exceeded earnings expectations and announced a $5 billion share repurchase program, influencing UPS's stock movement. UPS, which reported a revenue decline in its last quarterly results, is anticipated to announce its first-quarter results soon, with expectations set for earnings of $1.57 per share and revenue of $22.039 billion.

Portfolio Pulse from Erica Kollmann

March 21, 2024 | 9:02 pm

TELA

TELA Bio projects its full-year 2024 revenue to be between $74M and $76M, indicating a year-over-year growth of 27% to 30%. The estimated midpoint for this projection is $75.196M.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 9:00 pm

OSS

One Stop Systems (NASDAQ:OSS) reported Q4 earnings with an EPS of $0.01, beating estimates by 125% but with a revenue decrease of $5.09M from last year. The company has a history of beating EPS estimates, which previously led to a share price increase.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 9:00 pm

OSS

One Stop Systems (NASDAQ:OSS) reported Q4 earnings of $0.01 per share, surpassing the $(0.04) estimate, marking a 125% beat and a 107.14% increase from last year's $(0.14) loss per share. Q4 sales reached $13.15M, exceeding the $13.01M estimate by 1.11%, despite a 27.91% decrease from last year's $18.25M.

Portfolio Pulse from dijoy@benzinga.com

March 21, 2024 | 8:56 pm

BIOL

Biolase expects its Q1 net revenue to surpass $10M, showing no significant change year-over-year, against an estimate of $10.796M. The company also forecasts a 6%-8% increase in net revenue for 2024, aiming for $52M-$53M, slightly below the estimated $53.068M.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 8:55 pm

CUTR

Cutera (NASDAQ:CUTR) reported Q4 earnings with a significant miss on estimated earnings by -45.0%, posting an EPS of $-1.36 against an estimate of $-0.94. Revenue also saw a decline, down $17.81 million from the same period last year. This follows a pattern of missed EPS estimates in previous quarters, with the last quarter's miss leading to a 43.0% drop in share price the next day.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 8:50 pm

CUTR

Cutera shares are trading lower following the announcement of Q4 adjusted EPS results that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 8:47 pm

IDN

Intellicheck shares surged following the announcement of a year-over-year increase in Q4 EPS results.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 8:46 pm

CUTR

Cutera reported Q4 2023 adjusted EPS of $(1.36), missing the $(0.94) estimate, but sales of $49.540M exceeded the $47.500M estimate. This represents a 26.45% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 8:45 pm